Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net tislelizumab-jsgr Coverage Update | Ope…
    Ask Trek AI about this page
    ModifiedHealth NetPolicy CP PHAR.687

    Tislelizumab-jsgr (Tevimbra) coverage

    Customize your policy alerts

    Sign up for Health Net Policy CP PHAR.687 alerts

    Get alerted when Policy CP PHAR.687 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for tislelizumab-jsgr (Tevimbra) for adults with specified malignancies and describes coding implications and approval durations for Health Net lines of business.

    Policy Summary
    PayerHealth Net
    PolicyTislelizumab-jsgr (Tevimbra) coverage
    Policy CodePolicy CP PHAR.687
    Change TypeAdded HCPCS codeexpanded labeled and NCCN-supported indicationsclarified line-of-therapy
    Effective DateSep 1, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation that the member meets initial or continuation criteria and use HCPCS J9329 for requests.
    SourceLink
    POLICY UPDATE CHANGES

    Added HCPCS code J9329 and removed HCPCS codes J3590 and C93991.

    Updated criteria to include new indication for gastric/gastroesophageal junction adenocarcinoma (G/GEJ) in combination with platinum and fluoropyrimidine-based chemotherapy for PD-L1 positive tumors.

    Updated criteria to include first-line ESCC treatment in combination with platinum-containing chemotherapy for PD-L1 positive tumors and added an option for planned esophagectomy as bypass for unresectable disease criterion.

    Added HCPCS code J9329 and removed HCPCS codes J3590 and C93991.

    Updated criteria to include new indication for G/GEJ and first-line ESCC treatment in combination with platinum-containing chemotherapy for tumors expressing PD-L1; added multiple off-label indications supported by NCCN.

    For HCC, clarified criterion as first-line systemic therapy and added option to be prescribed as subsequent-line systemic therapy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    200 mgMax dose q3w
    6 moInitial approval
    12 moContinuation approval
    J9329Assigned HCPCS
    100 mgVial strength
    2HCPCS removed

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met for initial therapy:

    Initial Approval - General: 1. Diagnosis of ESCC or G/GEJ; 2. Prescribed by or in consultation with an oncologist; 3. Age >= 18 years; 4. Disease is unresectable, locally advanced, recurrent, or metastatic (for ESCC, planned esophagectomy satisfies the disease criterion as an alternative to 'unresectable'); 5. Dose does not exceed 200 mg IV every 3 weeks; 6. Prescribed regimen must be FDA‑approved or recommended by NCCN; 7. Approval duration: 6 months.

    Combine with disease-specific nodes below.

    ESCC specific: For ESCC either: (a) Prescribed as a single agent after prior systemic chemotherapy that did NOT include a PD‑(L)1 inhibitor and member previously received fluoropyrimidine‑ and platinum‑based chemotherapy; OR (b) Prescribed in combination with platinum‑containing chemotherapy for first‑line treatment or when member is planned for esophagectomy; when given in combination, tumor must be PD‑L1 positive.
    G/GEJ specific: For G/GEJ all of the following: disease is unresectable, locally advanced, recurrent, or metastatic; tumor is HER2‑negative; tumor is PD‑L1 positive; request is for first‑line treatment; Tevimbra is prescribed in combination with both a fluoropyrimidine‑containing chemotherapy and a platinum‑containing chemotherapy.

    Off-label/NCCN Recommended Uses

    NCCN‑Recommended Off‑label Uses (covered when ALL criteria met):

    Off‑label NCCN Uses: Prescribed as a single agent or in specified combinations for selected diagnoses supported by NCCN (examples include locally recurrent/progressive/metastatic anal carcinoma; small bowel adenocarcinoma; colorectal cancer with dMMR/MSI‑H or POLE/POLD1 mutation; hepatocellular carcinoma; head and neck cancers; and CLL/SLL with Richter transformation in combination with zanubrutinib per NCCN guidance). Prescribed by or in consultation with an oncologist; age >= 18 years; prescribed regimen must be FDA‑approved or NCCN‑recommended; dose is within FDA maximum limit or is supported by practice guidelines/peer‑reviewed literature (prescriber must submit supporting evidence for off‑label regimens). Prior authorization for zanubrutinib may be required.

    Prescriber must supply supporting evidence for off‑label uses not FDA‑approved.

    Continuation Therapy

    Continuation therapy criteria (must meet ALL):

    Continuation Therapy: 1. Member is currently receiving medication via Centene benefit or documentation confirms member has received Tevimbra for a covered indication for at least 30 days; 2. Member is responding positively to therapy; 3. New dose does not exceed 200 mg IV every 3 weeks; 4. If requesting a dose increase, the new dose must be supported by practice guidelines or peer‑reviewed literature for the relevant indication (prescriber must submit supporting evidence); 5. Prescribed regimen must be FDA‑approved or NCCN‑recommended; Approval duration: 12 months.

    Updated covered indications and line-of-therapy clarifications

    Criteria were updated to add labeled and off‑label oncology indications and to clarify line‑of‑therapy designations for specific cancers.

    Indication expansion: Added new indication for G/GEJ and first‑line ESCC treatment in combination with platinum‑containing chemotherapy for tumors expressing PD‑L1 per updated product information; for ESCC added bypass option when member is planned for esophagectomy; for G/GEJ added option for locally advanced or recurrent disease.

    Supported by updated prescribing information and P&T review.

    Off‑label indications: Added NCCN‑supported off‑label indications including anal carcinoma; CLL/SLL with Richter transformation to diffuse large B‑cell lymphoma; head and neck cancers; hepatocellular carcinoma (HCC); small bowel adenocarcinoma; and colorectal cancer.

    NCCN support required and prescriber must submit supporting evidence for off‑label uses not FDA‑approved.

    HCC line of therapy: For HCC, criterion clarified to allow use as first‑line systemic therapy and added an option to be prescribed as subsequent‑line systemic therapy.

    3Q 2025 annual review update.

    Coverage is NOT authorized for non‑FDA approved indications that are not specifically addressed in this policy unless the provider supplies sufficient documentation of efficacy and safety per the applicable off‑label use policies or evidence of coverage documents. See off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), and CP PMN.53 (Medicaid) for required supporting evidence and documentation pathways.

    This clinical policy is guidance to assist in medical necessity determinations but is not a contract or guarantee of payment. Coverage decisions and benefit administration remain subject to the terms, conditions, exclusions, and limitations of the member's coverage documents (for example, Evidence of Coverage, Certificate of Coverage, policy or contract). Where state Medicaid provisions conflict with this policy, the state Medicaid manual and requirements take precedence.

    Use of tislelizumab‑jsgr (Tevimbra) for indications not listed in this policy and lacking adequate supporting evidence per the referenced off‑label use policies is considered not authorized. Requests for such off‑label uses must follow the applicable off‑label policy requirements and include the evidence and justification specified by those policies.

    This policy provides clinical guidance on medical necessity criteria but does not guarantee payment. Providers must follow applicable coverage documents and administrative policies when submitting authorization requests; specific conditions that would render a request not medically necessary or not payable are detailed elsewhere in the member’s formulary, benefit, and administrative documents.

    Initial Therapy Criteria

    Initial Therapy

    Initial coverage rules:

    Initial Therapy Nodes: See 'Initial Therapy' criteria set: diagnosis of ESCC or G/GEJ; prescriber specialty (oncologist or in consultation); age >= 18 years; disease stage (unresectable/locally advanced/recurrent/metastatic) with ESCC bypass option for planned esophagectomy; PD‑L1 and HER2 tumor status requirements where applicable; prior therapy requirements for single‑agent ESCC; combination regimen requirements for first‑line use in G/GEJ and ESCC; dose limits (<= 200 mg IV every 3 weeks); regimen must be FDA‑approved or NCCN‑recommended; approval duration 6 months.

    Document prior therapies and absence of prior PD‑(L)1 inhibitor exposure when required.

    Initial therapy indications

    Initial therapy indications updated to include new labeled uses and NCCN‑supported off‑label uses.

    Initial therapy additions: Added indication for G/GEJ and first‑line ESCC combination therapy per updated product information; appendix and references updated; multiple NCCN‑supported off‑label indications added.

    Providers must request authorization using updated HCPCS code J9329 per coding implications.

    Continuation Therapy Criteria

    Continuation Therapy

    Criteria for continued coverage:

    Continuation: Member has documented ongoing benefit or has been on therapy at least 30 days; member is responding to therapy; dose is within limits or any increase is supported by guidelines or literature; duration of approval: 12 months.

    Request must include documentation of clinical response and dosing.

    HCC continuation therapy

    For HCC, continuation/subsequent‑line use was explicitly added as an option.

    HCC continuation: Criterion updated to allow tislelizumab‑jsgr to be prescribed as subsequent‑line systemic therapy in addition to first‑line systemic therapy for HCC.

    3Q 2025 annual review; providers should reference updated Appendix B for details.

    Coding and Dosing

    HCPCS codes referencedHCPCS
    J9329Injection, tislelizumab-jsgr, 1 mg
    J3590Removed — unclassified drug code (previously referenced)
    C93991Removed — miscellaneous oncology drug (previously referenced)
    HCPCS codes (added and removed)HCPCS
    J9329HCPCS code added (for tislelizumab-jsgr)
    J3590HCPCS code removed
    C93991HCPCS code removed
    inv-11: Maximum routine dosing
    Maximum routine dose200 mg IV every 3 weeks
    Approval duration (initial)6 months
    Dose increase requirementAny requested dose increase must be supported by practice guidelines or peer-reviewed literature for the relevant indication (prescriber must submit supporting evidence)
    inv-12: Review timeframe
    Next review timeframe3Q 2025
    HCC criterion update note3Q 2025 annual review clarified HCC as first-line systemic therapy and added option for subsequent-line use

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Provider must submit documentation that the member meets the policy's initial or continuation criteria (diagnosis, prescriber specialty, prior therapies, PD-L1/HER2 status where applicable) to support medical necessity determinations.

    • Affected HCPCS: J9329 (newly added). Removed HCPCS: J3590, C93991.
    Billing Rule

    Authorization Criteria Updated — Coding and Indications

    Authorization criteria were updated to add labeled and multiple off‑label oncology indications and to reflect updated coding. Providers should use HCPCS J9329 when billing and include supporting clinical documentation for any off‑label requests (dose, regimen, and citation to guideline or peer‑reviewed literature where required).

    Step Therapy / Sequencing

    StepRequirement
    1Provider documents prior systemic chemotherapy did NOT include a PD-(L)1 inhibitor and member previously received fluoropyrimidine- and platinum-based chemotherapy (e.g., 5‑fluorouracil or capecitabine plus cisplatin or oxaliplatin).
    2For ESCC when prescribed as a single agent after prior chemotherapy: submit clinical documentation confirming absence of prior PD-(L)1 inhibitor exposure and prior fluoropyrimidine- and platinum-based chemotherapy.
    3When requested in combination regimens (ESCC or G/GEJ): request must be for first-line treatment or member is planned for esophagectomy (ESCC). Tumor must be PD‑L1 positive for combination use.
    StepUpdated sequencing / notes
    1Updated criteria add first-line combination use for ESCC and G/GEJ: Tevimbra in combination with platinum-containing chemotherapy (ESCC) or with both platinum- and fluoropyrimidine-containing chemotherapy (G/GEJ) for PD‑L1 positive tumors.
    2For ESCC the policy allows a bypass of the 'unresectable' disease requirement when member is planned for esophagectomy; sequencing requirement remains that combination use is first-line.
    3For hepatocellular carcinoma (HCC) the criterion was clarified to allow first-line systemic therapy and added an option for subsequent-line systemic therapy (see 3Q 2025 update).
    4Off-label NCCN-supported indications (anal carcinoma, CLL/SLL with Richter transformation, head and neck cancers, small bowel adenocarcinoma, colorectal cancer) were added; off-label requests must meet NCCN-based sequencing and prescriber justification requirements.

    Quantity Limits and Product Info

    inv-33: Tislelizumab-jsgr (Tevimbra) — Product vial strength and quantity limit
    Product vial strength (policy note)100 mg/10 mL (product vial strength listed in policy appendices)
    Quantity limit (per administration)200 mg (maximum routine dose)
    Dosing intervalEvery 3 weeks

    Definitions

    inv-22: ESCC
    TermEsophageal squamous cell carcinoma
    AbbreviationESCC
    Context mentionListed in appendices/abbreviation key of the policy
    inv-23: G/GEJ
    TermGastric or gastroesophageal junction adenocarcinoma
    AbbreviationG/GEJ
    Treatment contextPolicy requires HER2-negative and PD-L1 positive tumor for first-line combination use

    Background

    Tislelizumab‑jsgr (brand name Tevimbra) is a PD‑1 blocking monoclonal antibody used in adults for select advanced malignancies. The product is indicated for certain unresectable or metastatic cancers including esophageal squamous cell carcinoma (ESCC) and specific gastric/gastroesophageal junction (G/GEJ) adenocarcinomas when used per the approved regimens and biomarker requirements.

    Policy Summary
    PayerHealth Net
    PolicyTislelizumab-jsgr (Tevimbra) coverage
    Policy CodePolicy CP PHAR.687
    Change TypeAdded HCPCS codeexpanded labeled and NCCN-supported indicationsclarified line-of-therapy
    Effective DateSep 1, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation that the member meets initial or continuation criteria and use HCPCS J9329 for requests.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation Therapy CriteriaCoding and DosingProvider Actions and RequirementsStep Therapy / SequencingQuantity Limits and Product InfoDefinitionsBackground
    Appendix B updateAppendix B was updated as part of the 3Q 2025 review
    • Add supporting evidence for off‑label indications per off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) and member's evidence of coverage.
    • When requesting coverage for newly added indications (e.g., G/GEJ, first‑line ESCC in combination with platinum agents for PD‑L1 positive tumors), include documentation of PD‑L1 status and prior/planned chemotherapy sequencing.
    Step Therapy

    Therapy Sequencing and Required Prior Therapy Documentation

    For esophageal squamous cell carcinoma (ESCC) when Tevimbra is prescribed as a single agent after prior chemotherapy, include documentation of prior fluoropyrimidine‑ and platinum‑based chemotherapy and sequencing rationale. If prescribed in combination with platinum‑containing chemotherapy as first‑line therapy, document PD‑L1 tumor status when required by the criteria.

    • Document prior systemic chemotherapy agents and dates (e.g., 5‑fluorouracil, capecitabine; cisplatin, oxaliplatin).
    • If member is planned for esophagectomy, include surgical plan to meet the bypass option for disease extent criteria.
    Documentation Required

    Required Clinical Documentation

    Provider must submit office chart notes, relevant lab results, pathology reports, PD‑L1 and HER2 testing results where applicable, and documentation of prior therapies to demonstrate the member meets all approval criteria.

    • Include treatment history (agents, dates, responses), imaging or surgical plans (e.g., planned esophagectomy), and tumor biomarker results (PD‑L1, HER2).
    • For continuation requests, document clinical benefit or stability and that member has been on therapy for at least 30 days when applicable.
    Denial Risk

    Insufficient Documentation / Non‑Covered Indications

    Failure to provide sufficient documentation that the member meets all approval criteria or requests for non‑FDA approved indications without adequate supporting evidence may result in denial. Follow applicable off‑label use policies and submit guideline or literature support when seeking coverage for off‑label indications.

    • Denial risk if documentation of prior therapies, biomarker status, or prescriber specialty is missing.
    • Off‑label requests must reference NCCN or peer‑reviewed literature and comply with CP.CPA.09, HIM.PA.154, or CP.PMN.53 as applicable.
    Note

    Documentation and Coverage Governance

    Providers must follow the Health Plan's coverage documents, administrative policies, and the clinical policy as guidance for medical necessity determinations. Coverage decisions remain subject to the member's contract terms, exclusions, and limitations.

    • Adhere to applicable plan‑level administrative policies and evidence of coverage when submitting requests.
    • This policy is effective as of the listed date and may be subject to legal/regulatory provider notification requirements.
    Note

    (Provider action placeholder) Include any additional provider‑action text or updates from source documents here as needed.

    inv-24: dMMR/MSI-H
    TermDeficient mismatch repair / microsatellite instability-high
    AbbreviationdMMR / MSI-H
    Use in policyReferenced in appendices as a biomarker for certain NCCN-supported off-label uses
    inv-25: Gastric/gastroesophageal junction cancer (G/GEJ) — alias definition
    Alias termG/GEJ (Gastric/gastroesophageal junction cancer)
    DefinitionGastric or gastroesophageal junction adenocarcinoma; policy specifies HER2-negative and PD-L1 positive criteria for first-line combination treatment
    Reference locationDefined in Appendix A: Abbreviation/Acronym Key
    inv-26: Esophageal squamous cell carcinoma (ESCC) — alias definition
    Alias termESCC (Esophageal squamous cell carcinoma)
    DefinitionEsophageal squamous cell carcinoma; policy includes first-line combination use for PD-L1 positive tumors and single-agent use after prior non–PD-(L)1 chemotherapy
    Reference locationDefined in Appendix A: Abbreviation/Acronym Key and expanded in coding/criteria updates